Neurobehavioral and genotoxic parameters of duloxetine in mice using the inhibitory avoidance task and comet assay as experimental models

Pharmacological Research

Volumn 59, Issue 1, 2009, Pages 57-61

  Pereira, Patrícia ^a   Gianesini, Janaína ^a   da Silva Barbosa, Cibele ^a   Cassol, Graziela Freitas ^a   Von Borowski, Rafael Gomes ^a   Kahl, Vivian Francília Silva ^a   Cappelari, Shandale Emanuele ^a   Picada, Jaqueline Nascimento ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Antidepressant; Comet assay; DNA damage; Duloxetine; Inhibitory avoidance; Memory

Indexed keywords

ANTIDEPRESSANT AGENT; DIZOCILPINE; DNA; DULOXETINE; HYDROGEN PEROXIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN FUNCTION; BRAIN TISSUE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; EXPERIMENTAL MODEL; GENOTOXICITY; LONG TERM MEMORY; MALE; MEMORY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SHORT TERM MEMORY; TASK PERFORMANCE;

ANIMALS; ANTIDEPRESSIVE AGENTS; AVOIDANCE LEARNING; COMET ASSAY; DNA DAMAGE; MALE; MEMORY; MICE; THIOPHENES;

EID: 58149279446     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.09.014     Document Type: Article

References (34)

1. Hunziker M.E., Suehs B.T., Bettinger T.L., and Crismon M.L. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 27 (2005) 1126-1141
2. Gupta S., Nihalani N., and Masand P. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry 19 (2007) 125-132
3. Rénéric J.P., and Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 136 (1998) 190-197
4. Bymaster F.P., Dreshfield-Ahmad L., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L., et al. Comparative affinity of duloixetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25 (2001) 871-880
5. Arenas M.C., Vinader-Caerols C., Monleón S., Martos A.J., Everss E., Ferrer-Añó A., et al. Are the effects of the antidepressants amitriptyline, maprotiline, and fluoxetine on inhibitory avoidance state-dependent?. Behav Brain Res 166 (2006) 150-158
6. Naudon L., Hotte M., and Jay T.M. Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine. Psychopharmacology (Berl) 191 (2007) 353-364
7. Jost W.H., and Marsalek P. Duloxetine in the treatment of stress urinary incontinence. Ther Clin Risk Manag 1 (2005) 259-264
8. Raskin J., Wiltse C.G., Siegal A., Sheikh J., Xu J., Dinkel J., et al. Efficacy of duloxetine on cognition, depression and pain, in elderly patients with major depressive disorder: Na 8-week, doublé-blind, placebo-controlled trial. Am J Psychiatry 164 (2007) 900-909
9. Roesler R., Walz R., Quevedo J., de-Paris F., Zanata S.M., Graner E., et al. Normal inhibitory avoidance learning and anxiety, but increased locomotor activity in mice devoid of PrP(C). Brain Res Mol Brain Res 71 (1999) 349-353
10. Pereira P., Oliveira P., Ardenghi P., Rotta L.N., Henriques J.A.P., and Picada J.N. Neuropharmacological analysis of caffeic acid in rats. Basic Clin Pharmacol Toxicol 99 (2006) 374-378
11. Picada J.N., Flores D.G., Zettler C.G., Marroni N.P., Roesler R., and Henriques J.A.P. DNA damage in brain cells of mice treated with an oxidized form of apomorphine. Mol Brain Res 114 (2003) 80-85
12. Hartmann A., Agurell E., Beevers C., Brendler-Schwaab S., Burlinson B., Clay P., et al. Recommendations for conducting the in vivo alkaline comet assay. Mutagenesis 18 (2003) 45-51
13. Brendler-Schwaab S., Hartmann A., Pfuhler S., and Speit G. The in vivo comet assay: use and status in genotoxicity testing. Mutagenesis 20 (2005) 245-254
14. Pereira P., Tysca D., Oliveira P., da Silva Brum L.F., Picada J.N., and Ardenghi P. Neurobehavioral and genotoxic aspects of rosmarinic acid. Pharmacol Res 52 (2005) 199-203
15. Viana C.C.S., Oliveira P., da Silva Brum L.F., Picada J.N., and Pereira P. Gamma-decanolactone effect on behavioral and genotoxic parameters. Life Sci 80 (2007) 1014-1019
16. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35 (2000) 206-221
17. Nadin S.B., Vargas-Roig M.L., and Ciocca D.R. A silver staining for single-cell gel assay. J Histochem Cytochem 49 (2001) 1183-1186
18. Monleon S., Vinader-Caerols C., Arenas M.C., and Parra A. Antidepressant drugs and memory: insights from animal studies. Eur Neuropsychopharmacol 18 (2008) 235-248
19. Mostert J.P., Koch M.W., Heerings M., Heersema D.J., and De Keyser J. Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther 14 (2008) 153-164
20. Ramanathan M., Kumar S.N., and Suresh B. Evaluation of cognitive function of fluoxetine, sertraline and tianeptine in isolation and chronic unpredictable mild stress-induced depressive Wistar rats. Indian J Exp Biol 41 (2003) 1269-1272
21. Izquierdo O., and Medina J.H. Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structure. Neurobiol Learn Mem 68 (1997) 285-316
22. Martí Barros D., Ramirez M.R., Dos Reis E.A., and Izquierdo I. Participation of hippocampal nicotinic receptors in acquisition, consolidation and retrieval of memory for one trial inhibitory avoidance in rats. Neuroscience 126 (2004) 651-656
23. Frampton J.E., and Plosker G.L. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 21 (2007) 581-609
24. Basu M., and Duckett J. The treatment of urinary incontinence with duloxetine. J Obstet Gynaecol 2 (2008) 166-169
25. Jones C.K., Peters S.C., and Shannon H.E. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 312 (2005) 726-732
26. Lantz R.J., Gillespie T.A., Rash T.J., Kuo F., Skinner M., Kuan H.Y., et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 31 (2003) 1142-1150
27. Picada J.N., Roesler R., and Henriques J.A.P. Genotoxic, neurotoxic and neuroprotective activities of apomorphine and its oxidized derivative 8-oxo-apomorphine. Braz J Med Biol Res 38 (2005) 477-486
28. Sasaki Y.F., Kawaguchi S., Kamaya A., Ohshita M., Kabasawa K., Iwama K., et al. The comet assay with 8 mouse organs: results with 39 currently used food additives. Mutat Res 519 (2002) 103-119
29. Halliwell B. Role of free radicals in the neurodegenerative diseases. Drugs Aging 18 (2001) 685-716
30. Frenzilli G., Scarcelli V., Fornai F., Paparelli A., and Nigro M. The comet assay as a method of assessment of neurotoxicity: usefulness for drugs of abuse. Ann N Y Acad Sci 1074 (2006) 478-481
31. Kalyanaraman B. Characterization of o-quinone radicals in biological systems. Methods Enzymol 186 (1990) 333-343
32. Bindolli A., Rigobello M.P., and Deeble D.J. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 13 (1992) 391-405
33. Smythies J.R. Oxidative reactions and schizophrenia. Schizophr Res 24 (1997) 357-364
34. Rueter L.E., Kasamo K., de Montigny C., and Blier P. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 357 (1998) 600-610